News25/Ratings7
News · 26 weeks56-25%
2025-12-072026-05-31
Mix4290d
- Insider24(57%)
- SEC Filings9(21%)
- Other5(12%)
- Earnings3(7%)
- Leadership1(2%)
Latest news
25 items- PRThe Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring ConferenceCERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D. Podnos, MD, MPH, FACS, Chief Medical Officer, will participate in a panel discussion at the APG Spring Conference on May 28, 2026, in San Diego. The session, "Engaging More Specialists in Value-Based Care," will bring together healthcare leaders to discuss the growing role of specialists in advancing value-based care. "Specialists play a critical role in delivering high-quality, coordinated care while helping improve outcomes and reduce the total cost of care," said Dr. Podnos. "As oncology c
- INSIDERChief Medical Officer Podnos Yale disposed of $8,068 worth of shares (1,805 units at $4.47), decreasing direct ownership by 0.63% to 282,978 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERChief Executive Officer Virnich Daniel disposed of $103,069 worth of shares (23,058 units at $4.47), decreasing direct ownership by 0.98% to 2,337,166 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERChief Financial Officer Carter Robert Ross disposed of $7,170 worth of shares (1,604 units at $4.47), decreasing direct ownership by 0.39% to 414,801 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Oncology Institute, Inc. (0001799191) (Filer)
- INSIDERLarge owner Chernett Jorey bought $156,595 worth of shares (38,500 units at $4.07), increasing direct ownership by 0.37% to 10,567,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERLarge owner Chernett Jorey bought $122,700 worth of shares (30,000 units at $4.09), increasing direct ownership by 0.29% to 10,529,358 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by The Oncology Institute Inc.SCHEDULE 13D/A - Oncology Institute, Inc. (0001799191) (Subject)
- PRThe Oncology Institute to Participate in B. Riley Securities Institutional Investor ConferenceCERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the B. Riley Securities Institutional Investor Conference, being held in Marina Del Rey, CA on Thursday, May 21, 2026, including a fireside chat from 9:00–9:40 a.m. PT. A webcast link of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.theoncologyinstitute.com/. ____________________________ About The Oncology Institute (www.theonco
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Oncology Institute, Inc. (0001799191) (Filer)
- SECSEC Form 10-Q filed by The Oncology Institute Inc.10-Q - Oncology Institute, Inc. (0001799191) (Filer)
- PRThe Oncology Institute Reports First Quarter 2026 Financial ResultsCERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2026. Recent Operational Highlights Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 78% in the quarter as compared to prior year same quarter, reflecting the volume growth across our membership and continued attachment rate improvements.Contract expansion bringing our total Medicare Advantage lives to 200,000 across 25 counties in Florida effective July 1, 2026. Preparing to launch our propr
- SECSEC Form DEFA14A filed by The Oncology Institute Inc.DEFA14A - Oncology Institute, Inc. (0001799191) (Filer)
- SECSEC Form DEF 14A filed by The Oncology Institute Inc.DEF 14A - Oncology Institute, Inc. (0001799191) (Filer)
- PRThe Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference CallCERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) a pioneer in value-based community oncology care, today announced that the company will release its first quarter 2026 financial results on Thursday, May 7, 2026, to be followed by a conference call the same day at 5:30 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-800-225-9448 or for international callers, 1-203-518-9708. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 11161701. The replay will be av
- INSIDERSEC Form 4 filed by Chief Administrative Officer England Kristin4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERSEC Form 4 filed by Chief Clinical Officer Langsam Jeffrey4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERSEC Form 4 filed by Kaushal Mohit4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECSEC Form 144 filed by The Oncology Institute Inc.144 - Oncology Institute, Inc. (0001799191) (Subject)
- INSIDERSEC Form 4 filed by Chernett Jorey4 - Oncology Institute, Inc. (0001799191) (Issuer)
- PRThe Oncology Institute Achieves $1.8 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 3, Marking Significant Period-Over-Period ImprovementCERRITOS, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ:TOI), a leading value-based oncology practice, achieved $1.8 million in Medicare savings during Performance Period 3 of the Centers for Medicare & Medicaid Services' Enhancing Oncology Model (EOM) through its California professional corporation, with savings equating to more than $6,400 per patient episode. This represents a significant increase from Performance Period 2, when TOI generated $1.1 million in savings, or more than $3,500 per episode. For the second consecutive performance period, TOI earned the maximum score on avoidable emergency department visits and hospital admissio
- PRThe Oncology Institute to Participate in the 25th Annual Needham Healthcare ConferenceCERRITOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the 25th Annual Needham Healthcare Conference, being held virtually on Wednesday, April 15, 2026, including a fireside chat at 3:45 p.m. ET. A webcast link of the presentation will be accessible through the Investor Relations section of the Company's website at https://investors.theoncologyinstitute.com/. About The Oncology Institute (www.theoncologyinstitute.com): Founded in 2007, The Oncology Insti
- PRThe Oncology Institute Names Minh Merchant Chief Legal OfficerCERRITOS, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Minh Merchant has joined the organization as Chief Legal Officer. In this role, Ms. Merchant will oversee legal, regulatory, compliance and privacy functions as TOI continues to scale. This role will be essential in enabling the company to continue its growth trajectory while further enhancing its mission to be a trusted healthcare partner to oncology patients and payors. Ms. Merchant has more than two decades of experience advising public and private healthcare organizations, including significant
- INSIDERSEC Form 4 filed by Langsam Jeffrey4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERSEC Form 4 filed by England Kristin4 - Oncology Institute, Inc. (0001799191) (Issuer)
TOI FAQ
7 questionsWhat does The Oncology Institute Inc. do?
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in...Where does TOI stock trade?
The Oncology Institute Inc. (TOI) is listed on NASDAQ.What sector and industry is TOI in?
The Oncology Institute Inc. operates in the Health Care sector, Medical/Nursing Services industry.When did The Oncology Institute Inc. go public?
The Oncology Institute Inc. (TOI) completed its IPO in 2020.What are analysts saying about TOI?
The Oncology Institute Inc. has had 7 recent analyst actions on file. The most recent action was from Needham: Buy with a $500.00 price target on 2025-11-25. Recent price targets range from $250.00 to $1000.00.What companies are similar to TOI?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), HIMS (Hims & Hers Health Inc.), CHE (Chemed Corp), AMED (Amedisys Inc), LHCG (LHC Group). Compare TOI side-by-side with any of them on Quantisnow.How can I track TOI on Quantisnow?
Quantisnow aggregates The Oncology Institute Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TOI to receive live email and push alerts on every new disclosure.